Table 1 Demographic and Clinical Characteristics of Patients with Vancomycin-Resistant Enterococcal Bloodstream Infection.
Variablea | Total (n = 114) | DAP (n = 27) | DAP + BLA (n = 87) | P a |
|---|---|---|---|---|
Demographics | ||||
Age (years) | 65.4 (53.5–78.2) | 62.6 (49.8–75.1) | 67.8 (54.8–80.5) | 0.23 |
Male | 61 (53.5) | 18 (66.7) | 43 (49.4) | 0.12 |
Body weight (kg) | 58.1 (50.8–64.9) | 61.5 (52.6–66.5) | 57.8 (49.9–63.8) | 0.10 |
Duration of prior hospitalization (days) | 24 (10–42) | 24 (17–66) | 24 (9–38) | 0.11 |
Underlying conditions | ||||
Charlson comorbidity score | 3 (2–5) | 3 (2–6) | 3 (2–5) | 0.82 |
Autoimmune disease | 4 (3.5) | 0 (0) | 4 (4.6) | 0.57 |
Liver cirrhosis | 18 (15.8) | 3 (11.1) | 15 (17.2) | 0.56 |
Diabetes mellitus | 32 (28.1) | 4 (14.8) | 28 (32.1) | 0.08 |
Chronic kidney disease | 35 (30.7) | 6 (22.2) | 29 (33.3) | 0.27 |
Any Malignancy | 62 (54.4) | 12 (44.4) | 50 (57.5) | 0.24 |
Solid tumor | 31 (27.4) | 4 (15.4) | 27 (31.0) | 0.12 |
Hematologic | 30 (26.3) | 10 (37.0) | 20 (23.0) | 0.15 |
Metastatic | 15 (13.2) | 6 (22.2) | 9 (10.3) | 0.19 |
Use of immunosuppressive agents | 54 (47.4) | 17 (63.0) | 37 (42.5) | 0.06 |
Steroid | 18 (15.8) | 6 (22.2) | 12 (13.8) | 0.37 |
Chemotherapy | 39 (34.2) | 14 (51.9) | 25 (28.7) | 0.03 |
Solid organ transplant recipient | 2 (1.8) | 0 (0) | 2 (2.3) | 0.99 |
Hematopoietic stem cell transplant recipient | 7 (6.1) | 2 (7.4) | 5 (5.7) | 0.67 |
Infection focus | ||||
CLABSI | 50 (43.9) | 14 (51.9) | 36 (41.4) | 0.34 |
CRBSI | 7 (6.1) | 1 (3.7) | 6 (6.9) | 0.99 |
Urinary tract infection | 20 (17.5) | 5 (18.5) | 15 (17.2) | 0.99 |
Intra-abdominal infection | 11 (9.6) | 1 (3.7) | 10 (11.5) | 0.46 |
Surgical site infection | 5 (4.4) | 1 (3.7) | 4 (4.6) | 0.99 |
Unknown | 25 (21.9) | 5 (18.5) | 20 (23.0) | 0.62 |
Clinical characteristics | ||||
Neutropenia (ANC < 500/μL) | 30 (26.3) | 8 (29.6) | 22 (25.3) | 0.65 |
Platelet count (×104/µL) | 7.8 (2.9–17) | 10.5 (2.6–21) | 7.7 (2.9–16.7) | 0.87 |
Thrombocytopenia (<50000/μL) | 35 (30.7) | 9 (33.3) | 26 (29.9) | 0.73 |
Ventilator use | 47 (41.2) | 12 (44.4) | 35 (40.2) | 0.70 |
Pitt bacteremia score | 3 (1–6) | 3 (1–6) | 3 (1–6) | 0.92 |
Concomitant aminoglycoside use | 4 (3.5) | 2 (7.4) | 2 (2.3) | 0.24 |
DAP dose (mg/kg) | 7.8 (6.8–8.7) | 7.7 (6.3–8.3) | 7.8 (6.8–9.1) | 0.33 |
DAP dose ≥9 mg/kg | 26 (22.8) | 4 (14.8) | 22 (25.3) | 0.26 |
DAP MIC 1 mg/L | 5 (4.4) | 0 (0) | 5 (5.8) | 0.69 |
DAP MIC 2 mg/L | 29 (25.4) | 7 (25.9) | 22 (25.3) | |
DAP MIC ≥4 mg/L | 80 (70.2) | 20 (74.1) | 60 (69.0) | |
Outcomes | ||||
Mortality at the end of daptomycin treatment | 44 (38.6) | 10 (37.4) | 34 (39.1) | 0.85 |
In-hospital mortality | 72 (63.2) | 16 (59.3) | 56 (64.4) | 0.63 |
Elevated creatinine kinase | 7 (6.1) | 1 (3.7) | 6 (6.9) | 0.99 |
